

## Appendix: Tables

1.	Sales January to June 2024 and 2023 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023 .....	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2024 vs. YTD June 2023 .....	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States .....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe .....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International .....	10
9.	Roche Group consolidated income statement for the six months ended 30 June 2024.....	11
10.	Roche Group core results reconciliation – Half Year 2024 .....	12
11.	Divisional core results reconciliation – Half Year 2024 .....	13
12.	Roche Group consolidated balance sheet .....	14
13.	Roche Group consolidated statement of cash flows.....	15

## 1. Sales January to June 2024 and 2023

CHF millions	Six months ended 30 June		% change	
	2024	2023	At CER	In CHF
Pharmaceuticals Division	22,637	22,511	5	1
United States	11,882	11,573	5	3
Europe	4,425	4,105	10	8
Japan	1,366	2,210	-28	-38
International*	4,964	4,623	17	7
Diagnostics Division	7,211	7,268	5	-1
Roche Group	29,848	29,779	5	0

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023

CHF millions	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023
Pharmaceuticals Div.	10,903	7	10,861	11	10,893	-2	10,921	2	11,716	9
United States	5,811	8	5,857	11	5,829	5	5,692	5	6,190	6
Europe	2,034	5	2,154	9	2,047	3	2,200	11	2,225	10
Japan	820	8	727	1	808	-50	649	-45	717	-3
International*	2,238	6	2,123	17	2,209	16	2,380	12	2,584	23
Diagnostics Division	3,554	-17	3,413	-5	3,770	4	3,478	2	3,733	8
Roche Group	14,457	0	14,274	7	14,663	0	14,399	2	15,449	9

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

### 3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2024 vs. YTD June 2023

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,359	8	2,411	5	639	12	-	-	309	27
Hemlibra	2,143	7	1,231	1	468	14	171	3	273	32
Perjeta	1,921	-2	694	-7	341	-16	66	-30	820	14
Tecentriq	1,798	2	898	-8	429	10	182	-2	289	32
Vabysmo	1,794	93	1,371	78	287	183	53	35	83	324
Actemra/RoActemra	1,276	3	595	6	363	-3	146	7	172	4
Xolair	1,110	10	1,110	10	-	-	-	-	-	-
Kadcyla	999	6	381	1	288	-1	46	2	284	23
Evrysdi	838	25	283	14	286	21	44	14	225	50
Phesgo	799	60	258	27	354	51	50	-	137	115
Alecensa	766	7	236	9	145	1	96	4	289	10
Herceptin	740	-11	138	-19	154	-14	8	-44	440	-5
MabThera/Rituxan	706	-17	422	-19	77	-17	9	-23	198	-11
Avastin	654	-16	199	-20	44	-20	102	-33	309	-4
Activase/TNKase	593	-2	561	-3	-	-	-	-	32	17
Polivy	513	54	255	112	86	9	92	-1	80	107
Gazyva	445	15	217	14	123	13	15	-16	90	29
Pulmozyme	225	-2	141	-8	39	2	-	26	45	20
Madopar	200	13	-	-	50	1	-	-	150	17
CellCept	197	4	12	-26	60	-5	18	-10	107	19
Enspryng	143	32	41	28	14	90	69	8	19	297
Xofluza	68	183	4	164	-	-	-	-	64	184
Columvi	67	**	40	**	14	-	-	-	13	-

Rozlytrek	62	63	24	20	10	36	4	22	24	227
Lunsumio	37	34	28	19	8	137	-	-	1	132
Elevidys	29	-	-	-	-	-	-	-	29	-
Cotellic	20	-27	8	-41	6	3	-	-	6	-22
Luxturna	10	26	10	26	-	-	-	-	-	-
Piasky	2	-	-	-	-	-	2	-	-	-
Ronapreve	2	-100	-	-	2	**	-	-100	-	-99
Susvimo	1	-26	1	-26	-	-	-	-	-	-
Pharma other	1,120	-26	312	-46	138	-19	193	-26	477	-5
Pharma total sales	22,637	5	11,882	5	4,425	10	1,366	-28	4,964	17

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%

**4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth**

CHF millions	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023
Ocrevus	1,564	15	1,567	12	1,614	9	1,658	8	1,701	9
Hemlibra	1,053	17	1,025	17	1,035	9	1,040	8	1,103	6
Perjeta	1,033	6	913	0	773	-11	936	-3	985	-1
Tecentriq	933	8	938	10	975	5	865	1	933	2
Vabysmo	525	*	656	309	744	160	847	108	947	81
Actemra/RoActemra	620	2	647	21	687	13	618	-2	658	8
Xolair	552	4	570	3	575	7	496	10	614	11
Kadcyla	492	-5	485	5	480	13	483	3	516	9
Evrysdi	342	36	360	41	354	22	356	7	482	42
Phesgo	276	67	300	61	303	58	388	70	411	52
Alecensa	386	11	368	7	376	7	355	4	411	10
Herceptin	401	-22	383	-13	365	-14	364	-17	376	-4
MabThera/Rituxan	423	-17	378	-13	370	-15	351	-18	355	-15
Avastin	421	-17	373	-18	363	-15	324	-15	330	-18
Activase/TNKase	319	9	282	-4	270	-1	296	4	297	-7
Polivy	203	129	252	144	232	74	250	81	263	34
Gazyva	205	20	213	22	196	12	213	16	232	15
Pulmozyme	111	-15	104	-15	110	-6	112	-6	113	2
Madopar	98	18	89	-4	81	-4	91	11	109	14
CellCept	98	-19	94	-9	98	-8	94	0	103	9

\* Over 500%

**5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States**

CHF millions	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023
Ocrevus	1,158	14	1,146	10	1,192	8	1,180	5	1,231	6
Hemlibra	616	14	615	15	631	8	592	-1	639	3
Perjeta	371	6	338	-6	235	-35	343	-7	351	-6
Tecentriq	493	5	476	4	465	-4	436	-9	462	-7
Vabysmo	428	458	532	276	594	142	650	91	721	68
Actemra/RoActemra	278	6	303	33	346	33	278	-1	317	13
Xolair	552	4	570	3	575	7	496	10	614	11
Kadcyla	188	-5	182	-2	189	3	186	-1	195	3
Evrysdi	131	19	126	14	124	11	135	16	148	13
Phesgo	111	53	111	54	103	27	126	36	132	18
Alecensa	115	14	119	4	127	13	104	4	132	14
Herceptin	85	-23	82	-21	73	-20	67	-22	71	-16
MabThera/Rituxan	260	-19	227	-19	226	-22	204	-21	218	-17
Avastin	123	-20	114	-19	114	-9	99	-22	100	-18
Activase/TNKase	304	9	267	-5	253	-1	282	4	279	-9
Polivy	78	91	106	161	110	173	117	166	138	80
Gazyva	95	18	103	24	98	14	100	7	117	22
Pulmozyme	75	-16	71	-19	74	-9	66	-15	75	-2
Madopar	-	-	-	-	-	-	-	-	-	-
CellCept	8	-14	6	-34	8	-1	5	-34	7	-18

\* Over 500%

**6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe**

CHF millions	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023
Ocrevus	286	16	293	10	289	11	310	8	329	15
Hemlibra	213	18	218	22	208	8	231	17	237	12
Perjeta	193	-12	202	0	161	-21	171	-19	170	-12
Tecentriq	203	7	230	22	217	2	210	12	219	8
Vabysmo	59	*	82	*	91	406	138	224	149	153
Actemra/RoActemra	190	0	200	11	192	-1	188	1	175	-8
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	144	-15	148	-6	131	-17	145	-2	143	0
Evryssi	128	61	133	35	135	39	137	27	149	16
Phesgo	126	55	144	47	150	49	169	55	185	47
Alecensa	75	5	72	5	72	1	72	3	73	-1
Herceptin	86	-18	88	-9	82	-10	77	-17	77	-12
MabThera/Rituxan	45	-9	44	-11	40	-15	39	-20	38	-14
Avastin	27	-51	21	-50	20	-43	21	-27	23	-14
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	40	76	56	53	37	-21	54	42	32	-23
Gazyva	56	22	63	29	55	18	62	17	61	9
Pulmozyme	19	-20	18	-18	19	-15	20	0	19	3
Madopar	25	-1	25	-5	24	-4	24	-1	26	2
CellCept	31	-5	31	-4	28	-14	32	0	28	-9

\* Over 500%



**7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan**

CHF millions	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	100	19	89	5	92	5	79	2	92	4
Perjeta	56	5	52	6	54	3	36	-19	30	-39
Tecentriq	109	11	99	5	106	3	86	-4	96	0
Vabysmo	25	299	24	77	28	42	23	33	30	38
Actemra/RoActemra	80	5	75	4	79	3	68	5	78	9
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	26	-17	25	-15	25	-6	21	-4	25	8
Evrysdi	24	25	22	21	26	19	20	13	24	16
Phesgo	-	-	-	-	4	-	19	-	31	-
Alecensa	57	7	50	5	55	5	43	3	53	5
Herceptin	8	-34	7	-35	6	-31	4	-41	4	-48
MabThera/Rituxan	7	-15	6	-11	5	-15	4	-20	5	-26
Avastin	86	-25	73	-28	68	-31	51	-33	51	-34
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	57	194	59	178	60	55	44	2	48	-5
Gazyva	12	1	8	-18	10	-4	6	-19	9	-14
Pulmozyme	-	-4	-	33	1	-4	-	27	-	24
Madopar	-	-	-	-	-	-	-	-	-	-
CellCept	11	-8	11	-15	11	-12	9	-10	9	-11

**8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\***

CHF millions	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023
Ocrevus	120	23	128	50	133	22	168	28	141	27
Hemlibra	124	31	103	39	104	14	138	51	135	16
Perjeta	413	18	321	4	323	21	386	14	434	14
Tecentriq	128	23	133	18	187	39	133	34	156	30
Vabysmo	13	**	18	**	31	**	36	397	47	281
Actemra/RoActemra	72	-9	69	20	70	-3	84	-15	88	32
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	134	11	130	41	135	91	131	19	153	27
Evrysdi	59	39	79	134	69	18	64	-29	161	169
Phesgo	39	206	45	151	46	196	74	165	63	75
Alecensa	139	13	127	10	122	5	136	5	153	15
Herceptin	222	-22	206	-11	204	-12	216	-14	224	6
MabThera/Rituxan	111	-14	101	4	99	2	104	-11	94	-12
Avastin	185	1	165	-5	161	-4	153	3	156	-11
Activase/TNKase	15	8	15	-1	17	-1	14	7	18	25
Polivy	28	339	31	422	25	214	35	181	45	72
Gazyva	42	29	39	18	33	2	45	47	45	14
Pulmozyme	17	-5	15	14	16	18	26	22	19	17
Madopar	73	27	64	-4	57	-4	67	16	83	18
CellCept	48	-28	46	-6	51	-4	48	8	59	30

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%

## 9. Roche Group consolidated income statement for the six months ended 30 June 2024

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
<b>Sales</b>	<b>22,637</b>	<b>7,211</b>	-	<b>29,848</b>
Other revenue	886	22	-	908
Cost of sales	(4,536)	(3,334)	-	(7,870)
Research and development	(6,408)	(980)	-	(7,388)
Selling, general and administration	(3,400)	(1,510)	(1,942)	(6,852)
Other operating income and expense	414	16	(5)	425
<b>Operating profit</b>	<b>9,593</b>	<b>1,425</b>	<b>(1,947)</b>	<b>9,071</b>
Financing costs				(708)
Other financial income (expense)				(140)
<b>Profit before taxes</b>				<b>8,223</b>
Income taxes				(1,526)
<b>Net income</b>				<b>6,697</b>
Attributable to				
- Roche shareholders				6,258
- Non-controlling interests				439
<b>Earnings per share and non-voting equity security</b>				
Basic (CHF)				7.85
Diluted (CHF)				7.80

## 10. Roche Group core results reconciliation – Half Year 2024

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
<b>Sales</b>	<b>29,848</b>	-	-	-	-	-	-	-	-	<b>29,848</b>
Other revenue	908	-	-	-	-	-	-	-	-	908
Cost of sales	(7,870)	80	172	318	-	-	-	-	-	(7,300)
Research and development	(7,388)	215	172	733	-	-	-	-	-	(6,268)
Selling, general and administration	(6,852)	465	11	-	-	-	-	-	-	(6,376)
Other operating income and expense	425	2	-	-	32	22	-	-	-	481
<b>Operating profit</b>	<b>9,071</b>	<b>762</b>	<b>355</b>	<b>1,051</b>	<b>32</b>	<b>22</b>	-	-	-	<b>11,293</b>
Financing costs	(708)	-	-	-	5	5	-	-	-	(698)
Other financial income (expense)	(140)	-	-	-	-	-	-	-	-	(140)
<b>Profit before taxes</b>	<b>8,223</b>	<b>762</b>	<b>355</b>	<b>1,051</b>	<b>37</b>	<b>27</b>	-	-	-	<b>10,455</b>
Income taxes	(1,526)	(140)	(23)	(143)	(3)	(6)	-	-	37	(1,804)
<b>Net income</b>	<b>6,697</b>	<b>622</b>	<b>332</b>	<b>908</b>	<b>34</b>	<b>21</b>	-	-	<b>37</b>	<b>8,651</b>
Attributable to										
- Roche shareholders	6,258	616	331	908	34	21	-	-	37	8,205
- Non-controlling interests	439	6	1	-	-	-	-	-	-	446
EPS - diluted (CHF)	7.80	0.77	0.41	1.13	0.04	0.03	-	-	0.05	10.23



## 12. Roche Group consolidated balance sheet

in millions of CHF	30 June 2024	31 December 2023	31 December 2022
<b>Non-current assets</b>			
Property, plant and equipment	22,526	21,724	23,075
Right-of-use assets	1,336	1,215	1,133
Goodwill	10,995	9,390	10,820
Intangible assets	16,309	14,828	9,685
Deferred tax assets	7,632	6,882	6,427
Defined benefit plan assets	1,222	1,019	957
Other non-current assets	2,137	1,964	2,238
<b>Total non-current assets</b>	<b>62,157</b>	<b>57,022</b>	<b>54,335</b>
<b>Current assets</b>			
Inventories	7,945	7,749	8,605
Accounts receivable	12,173	11,021	11,606
Current income tax assets	306	344	313
Other current assets	3,643	3,822	3,525
Marketable securities	3,990	5,134	4,776
Cash and cash equivalents	4,824	5,376	4,991
Assets held for sale	748		
<b>Total current assets</b>	<b>33,629</b>	<b>33,446</b>	<b>33,816</b>
<b>Total assets</b>	<b>95,786</b>	<b>90,468</b>	<b>88,151</b>
<b>Non-current liabilities</b>			
Long-term debt	(28,420)	(24,809)	(21,391)
Net deferred tax liabilities	(635)	(593)	(645)
Defined benefit plan liabilities	(4,348)	(4,379)	(4,561)
Provisions	(1,169)	(1,059)	(1,111)
Other non-current liabilities	(1,739)	(1,541)	(1,189)
<b>Total non-current liabilities</b>	<b>(36,311)</b>	<b>(32,381)</b>	<b>(28,897)</b>
<b>Current liabilities</b>			
Short-term debt	(6,021)	(4,400)	(3,960)
Current income tax liabilities	(2,596)	(2,257)	(3,187)
Provisions	(1,774)	(1,684)	(2,248)
Accounts payable	(3,994)	(4,325)	(4,556)
Other current liabilities	(12,206)	(12,158)	(13,288)
Liabilities directly associated with assets held for sale	(8)		
<b>Total current liabilities</b>	<b>(26,599)</b>	<b>(24,824)</b>	<b>(27,239)</b>
<b>Total liabilities</b>	<b>(62,910)</b>	<b>(57,205)</b>	<b>(56,136)</b>
<b>Total net assets</b>	<b>32,876</b>	<b>33,263</b>	<b>32,015</b>
<b>Equity</b>			
Capital and reserves attributable to Roche shareholders	28,942	29,315	27,992
Equity attributable to non-controlling interests	3,934	3,948	4,023
<b>Total equity</b>	<b>32,876</b>	<b>33,263</b>	<b>32,015</b>

### 13. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2024	HY 2023
<b>Cash flows from operating activities</b>		
Cash generated from operations	12,772	12,091
(Increase) decrease in net working capital	(2,100)	(1,804)
Payments made for defined benefit plans	(313)	(314)
Utilisation of provisions	(469)	(505)
Other operating cash flows	-	-
<b>Cash flows from operating activities, before income taxes paid</b>	<b>9,890</b>	<b>9,468</b>
Income taxes paid	(1,976)	(1,570)
<b>Total cash flows from operating activities</b>	<b>7,914</b>	<b>7,898</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(1,724)	(1,740)
Purchase of intangible assets	(368)	(234)
Disposal of property, plant and equipment	19	33
Disposal of intangible assets	-	-
Disposal of products	353	585
Business combinations	(2,456)	-
Divestment of subsidiaries	-	-
Interest and dividends received	106	57
Sales of marketable securities	130	65
Purchases of marketable securities	(78)	(82)
Sales (purchases) of money market instruments and time accounts over three months, net	1,168	782
Other investing cash flows	(15)	52
<b>Total cash flows from investing activities</b>	<b>(2,865)</b>	<b>(482)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of bonds and notes	4,852	1,238
Redemption and repurchase of bonds and notes	(1,849)	(645)
Increase (decrease) in commercial paper	713	(41)
Increase (decrease) in other debt	40	(19)
Hedging and collateral arrangements	(108)	139
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(521)	(368)
Principal portion of lease liabilities paid	(172)	(174)
Dividends paid	(7,889)	(7,789)
Equity-settled equity compensation plans, net of transactions in own equity	(514)	(633)
Other financing cash flows	(1)	(1)
<b>Total cash flows from financing activities</b>	<b>(5,449)</b>	<b>(8,293)</b>
Net effect of currency translation on cash and cash equivalents	(152)	(394)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>(552)</b>	<b>(1,271)</b>
Cash and cash equivalents at beginning of period	5,376	4,991
<b>Cash and cash equivalents at end of period</b>	<b>4,824</b>	<b>3,720</b>